Ekf Diagnostics Regulatory News (EKF)

EKF Diagnostics Holdings plc

("EKF" or the "Company")

Notice of results

Investor briefing

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, will announce its interim results for the six months ended 30 June 2020 on Monday 14 September 2020.

Investor briefing

EKF Diagnostics will be hosting a live online presentation open to all investors on Monday 14 September at 4.30pm. The Company is committed to providing an opportunity for all existing and potential investors to hear directly from management on the recent developments and additionally providing an update on the business.

The presentation will be hosted through the digital platform Investor Meet Company. Investors can sign up to Investor Meet Company for free and click 'add to meet' EKF Diagnostics via the following link:

https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor

For those investors who have already registered and added to meet the Company, they will automatically be invited.

Questions can be submitted pre-event via the Investor Meet Company dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will aim to address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

About EKF Diagnostics Holdings plc

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.